Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050

Peds Open Studies

Registry

COG-APEC14B1	Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Albert Kheradpour, MD

CNS

COG-ACNS0332	Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients https://clinicaltrials.gov/ct2/show/NCT00392327 ONLY Stratum A & B are OPEN to enrollment	Albert Kheradpour, MD
COG-ACNS0831	Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years http://www.clinicaltrials.gov/ct2/show/NCT01096368	Albert Kheradpour, MD
COG-ACNS1422	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients https://clinicaltrials.gov/ct2/show/NCT02724579	Albert Kheradpour, MD

Ewing's Sarcoma

COG-AEWS1221	Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma https://clinicaltrials.gov/ct2/show/NCT02306161	Albert Kheradpour, MD

Germ Cell

COG-A031102	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors https://clinicaltrials.gov/ct2/show/NCT02375204	Albert Kheradpour, MD
COG-AGCT1531	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors https://clinicaltrials.gov/ct2/show/NCT03067181	Albert Kheradpour, MD

Hodgkin's Lymphoma

COG-AHOD1331	A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults https://clinicaltrials.gov/ct2/show/NCT02166463	Albert Kheradpour, MD

Hodgkin's Lymphoma continued

COG-AHOD1721	Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation https://clinicaltrials.gov/ct2/show/NCT02927769	Albert Kheradpour, MD

Kidney

COG-AREN03B2	Renal Tumors Classification, Biology and Banking Study http://clinicaltrials.gov/ct2/show/NCT00898365	Albert Kheradpour, MD

Leukemia

COG-AALL05B1	A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens http://clinicaltrials.gov/ct2/show/NCT00897325	Albert Kheradpour, MD
COG-AALL08B1	Classification of Newly Diagnosed Acute Lymphoblastic Leukemia http://www.clinicaltrials.gov/ct2/show/NCT01142427	Albert Kheradpour, MD
COG-AALL0932	Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or localized B-Lingeage Lymphoblastic Lymphoma (B-LLy) https://clinicaltrials.gov/ct2/show/NCT01190930 Low Risk Arms C & M are CLOSED to enrollment Average Risk Post-Induction / Pre-Maintenance is CLOSED to enrollment	Albert Kheradpour, MD
COG-AALL1131	A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND #73789, NSC #606869) in the Very High Risk Stratum https://clinicaltrials.gov/ct2/show/NCT01406756	Albert Kheradpour, MD
COG-AALL1331	Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) https://clinicaltrials.gov/ct2/show/NCT02101853	Albert Kheradpour, MD
COG-AALL1521	A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia https://clinicaltrials.gov/ct2/show/NCT02723994	Albert Kheradpour, MD
COG-AALL15P1	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement https://clinicaltrials.gov/ct2/show/NCT02828358	Albert Kheradpour, MD

Leukemia – continued

COG-AALL1631	International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones https://clinicaltrials.gov/ct2/show/NCT03007147	Albert Kheradpour, MD
COG-AAML1331	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid https://clinicaltrials.gov/ct2/show/NCT02339740	Albert Kheradpour, MD
COG-AAML1421	A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) https://clinicaltrials.gov/ct2/show/NCT02642965	Albert Kheradpour, MD
COG-AAML1531	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome https://clinicaltrials.gov/ct2/show/NCT02521493	Albert Kheradpour, MD
COG-ACCL1333	A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase https://clinicaltrials.gov/ct2/show/NCT02369653	Albert Kheradpour, MD

Liver

COG-AHEP0731	Treatment of Children with All Stages of Hepatoblastoma http://clinicaltrials.gov/ct2/show/NCT00980460 ONLY Stratum 1 and 4 are OPEN to enrollment	Albert Kheradpour, MD

Lymphoma

COG-ADVL1621	A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051) https://clinicaltrials.gov/ct2/show/NCT02332668	Albert Kheradpour, MD

Neuroblastoma

COG-ANBL00B1	Neuroblastoma Biology Studies http://clinicaltrials.gov/ct2/show/NCT00904241	Albert Kheradpour, MD
COG-ANBL1232	Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma http://clinicaltrials.gov/ct2/show/NCT02176967	Albert Kheradpour, MD

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Peds Open Studies

Rhabdomyosarcoma

COG-ARST1321	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC #737754, IND #118613) http://clinicaltrials.gov/ct2/show/NCT02180867 ONLY Stratum 1 – Regimen A & B are OPEN to enrollment	Albert Kheradpour, MD
COG-ARST1431	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) https://clinicaltrials.gov/ct2/show/NCT02567435	Albert Kheradpour, MD

Solid Tumors

COG-ADVL1621	A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051) https://clinicaltrials.gov/ct2/show/NCT02332668	Albert Kheradpour, MD
COG-ADVL1622	Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02867592 Only Stratum 1 is OPEN to enrollment	Albert Kheradpour, MD
ANHL1522	A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) https://clinicaltrials.gov/ct2/show/NCT02900976	Albert Kheradpour, MD

Stem Cell Transplant

NMDP-10-CBA	A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications http://www.clinicaltrials.gov/ct2/show/NCT01351545	Rishikesh Chavan, MD
NMDP-RESEARCH DATABASE	Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries http://www.clinicaltrials.gov/ct2/show/NCT00495300	Rishikesh Chavan, MD
NMDP-SAMPLE REPOSITORY	Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries http://www.clinicaltrials.gov/ct2/show/NCT00495300	Rishikesh Chavan, MD